Sarah Roden

About the Author Sarah Roden

Sarah writes about stock market news for TipRanks. She graduated as member of Phi Beta Kappa from the University of Richmond in Richmond, Virginia.

RBC Capital’s 2Q Earnings Preview: Amazon.com, Inc. (AMZN), Facebook Inc (FB), Alphabet Inc (GOOGL)

Top analyst Mark Mahaney at RBC Capital weighs in on internet giants Amazon.com, Inc. (NASDAQ:AMZN), Facebook Inc …

Read more

UBS Remains Bullish on Stanley Black & Decker, Inc. (SWK) Following Earnings

UBS analyst Shannon O’Callaghan weighed in on Stanley Black & Decker, Inc. (NYSE:SWK) following the …

Read more

BMO Remains Bearish on Whole Foods Market, Inc. (WFM)

Analyst Kelly Bania of BMO Capital weighed in on Whole Foods Market, Inc. (NASDAQ:WFM), expanding …

Read more

Alaska Air Group, Inc. (ALK) Upgraded to Buy, Positive Catalysts Ahead

Credit Suisse analyst Julie Yates weighed in on Alaska Air Group, Inc. (NYSE:ALK) in light …

Read more

Credit Suisse Analyst Downgrades LaSalle Hotel Properties (LHO) from Buy to Hold

Credit Suisse analyst Ian Weissman weighed in on LaSalle Hotel Properties (NYSE: LHO) downgrading the …

Read more

Credit Suisse Bearish on Ashford Hospitality Trust, Inc. (AHT); Downgrades and Cuts Price Target

Credit Suisse analyst Ian Weissman weighs in on Ashford Hospitality Trust, Inc. (NYSE:AHT) after taking …

Read more

Credit Suisse Bullish on Kellogg Company (K), Raises Price Target

Robert Moskow of Credit Suisse weighed in on Kellogg Company (NYSE:K) after taking a closer …

Read more

Piper Jaffray Downgrades Guess?, Inc. (GES) Due to Several Concerns

Erinn Murphy of Piper Jaffray commented on Guess?, Inc. (NYSE:GES) as she lowers her expectations …

Read more

UBS Remains Bullish on Nike Inc (NKE) Following Survey Results

UBS analyst Michael Binetti weighed in on Nike Inc (NYSE:NKE) following a survey on sportswear …

Read more

Piper Jaffray Cautious On Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Following Guidance Revision

Following Teva’s guidance revision, Piper Jaffray analyst David Amsellem maintained a Neutral rating on Teva …

Read more